Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21970988 | 0.85 | MAPK14 (0.36) | MEN1KMT2AMAPK14CNR2 | |
| SCHEMBL22560698 | 0.85 | MEN1 (0.40) | MEN1KMT2AEGFRMAPK14HPGD | |
| SCHEMBL24033648 | 0.85 | MAPK14 (0.39) | MEN1KMT2AMAPK14CNR1CNR2 | |
| SCHEMBL18643230 | 0.84 | ALDH1A1 (0.38) | MEN1KMT2AEGFRMAPK14CNR2 | |
| SCHEMBL9891487 | 0.82 | EGFR (0.42) | MEN1KMT2AEGFRMAPK14HPGD | |
| SCHEMBL24033649 | 0.82 | MAPK14 (0.34) | MEN1KMT2AMAPK14 | |
| SCHEMBL84872 | 0.81 | MEN1 (0.48) | MEN1KMT2AEGFRMAPK14HPGD | |
| SCHEMBL9891491 | 0.79 | CNR1 (0.39) | MEN1KMT2AEGFRMAPK14HPGD | |
| SCHEMBL18642861 | 0.79 | MAPK14 (0.33) | MAPK14 | |
| SCHEMBL25803019 | 0.78 | MEN1 (0.38) | MEN1KMT2AEGFRMAPK14HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | MEN1 1766/4885KMT2A 2554/4885EGFR 4553/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MEN1 2033/4885KMT2A 1484/4885EGFR 504/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | MEN1 3098/4885KMT2A 4530/4885EGFR 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.